STC2

Across TCGA pan-cancer cohorts, STC2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated STC2 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher STC2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated STC2 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where STC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.344	0.784	<.001	51	view →
CCRCC	DFS	Quartile	All	0.533	0.839	.003	25	view →
LUAD	OS	Tertile	III,IV	0.268	0.739	.007	19	view →
UCEC	OS	Quartile	All	0.834	1.000	.020	2	view →
GBM	OS	Quartile	All	0.490	0.188	.037	2	view →
LSCC	DFS	Tertile	II,III,IV	0.866	0.610	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

STC2–PDAC (OS)

Open the PDAC breakdown →